已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

医学 埃罗替尼 吉西他滨 奥沙利铂 内科学 化疗 肿瘤科 盐酸厄洛替尼 胰腺癌 癌症 胆道 胃肠病学 结直肠癌 表皮生长因子受体
作者
Jeeyun Lee,Se Hoon Park,Heung-Moon Chang,Jun Suk Kim,Hye Jin Choi,Myung Ah Lee,Joung Soon Chang,Hei‐Cheul Jeung,Jung Hun Kang,Hyun Woo Lee,Dong Bok Shin,Hye Jin Kang,Jong‐Mu Sun,Joon Oh Park,Young Suk Park,Won Ki Kang,Ho Yeong Lim
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:13 (2): 181-188 被引量:478
标识
DOI:10.1016/s1470-2045(11)70301-1
摘要

Combination chemotherapy with gemcitabine and a platinum-based agent is regarded as a standard treatment for patients with advanced biliary-tract cancer. Results of phase 2 trials of single-agent erlotinib in biliary-tract cancer and of gemcitabine plus erlotinib in pancreatic cancer have shown modest benefits. Therefore, we aimed to investigate the efficacy of gemcitabine and oxaliplatin plus erlotinib versus chemotherapy alone for advanced biliary-tract cancer.In this open label, randomised, phase 3 trial, we randomly assigned patients (in a 1:1 ratio) with metastatic biliary-tract cancer (cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer) to receive either first-line treatment with chemotherapy alone (gemcitabine 1000 mg/m(2) on day 1 and oxaliplatin 100 mg/m(2) on day 2) or chemotherapy plus erlotinib (100 mg daily). Treatment was repeated every 2 weeks until disease progression or unacceptable toxic effects. Randomisation was done centrally (stratified by participating centre and presence of measurable lesion). The primary endpoint was progression-free survival. Analyses were by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT01149122.133 patients were randomly assigned to the chemotherapy alone group and 135 to the chemotherapy plus erlotinib group. The groups were balanced except for a higher proportion of patients with cholangiocarcinoma in the group given erlotinib than in the chemotherapy alone group (96 [71%] patients vs 84 [63%]). Median progression-free survival was 4·2 months (95% CI 2·7-5·7) in the chemotherapy alone group and 5·8 months (95% CI 4·6-7·0) in the chemotherapy plus erlotinib group (hazard ratio [HR] 0·80, 95% CI 0·61-1·03; p=0·087). Significantly more patients had an objective response in the chemotherapy plus erlotinib group than in the chemotherapy alone group (40 patients vs 21 patients; p=0·005), but median overall survival was the same in both groups (9·5 months [95% CI 7·5-11·5] in the chemotherapy alone group and 9·5 months [7·6-11·4] in the chemotherapy plus erlotinib group; HR 0·93, 0·69-1·25; p=0·611). All-cause deaths within 30 days of random assignment occurred in one (1%) of the patients in the chemotherapy alone group and in four (3%) of those in the chemotherapy plus erlotinib group. The most common grade 3-4 adverse event was febrile neutropenia (eight [6%] patients in the chemotherapy alone group and six [4%] in the chemotherapy plus erlotinib group). No patient died of treatment-related causes during the study. Subgroup analyses by primary site of disease showed that for patients with cholangiocarcinoma, the addition of erlotinib to chemotherapy significantly prolonged median progression-free survival (5·9 months [95% CI 4·7-7·1] for chemotherapy plus erlotinib vs 3·0 months [1·1-4·9] for chemotherapy alone; HR 0·73, 95% CI 0·53-1·00; p=0·049).Although no significant difference in progression-free survival was noted between groups, the addition of erlotinib to gemcitabine and oxaliplatin showed antitumour activity and might be a treatment option for patients with cholangiocarcinoma.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
芝士小歪发布了新的文献求助10
刚刚
1秒前
乐乐的应助被Apple采纳,获得10
2秒前
猪四郎完成签到 ,获得积分10
4秒前
hjzno_1完成签到 ,获得积分10
6秒前
pik完成签到,获得积分20
8秒前
五岳三鸟完成签到,获得积分10
8秒前
摇摇晃晃完成签到 ,获得积分10
9秒前
9秒前
9秒前
10秒前
11秒前
SciGPT的应助被手提袋子的猫采纳,获得10
11秒前
12秒前
长情的寇完成签到 ,获得积分10
12秒前
77完成签到,获得积分10
12秒前
12秒前
13秒前
木华发布了新的文献求助10
14秒前
14秒前
胡图图完成签到 ,获得积分20
14秒前
酷波er的应助被无情妙菡采纳,获得10
15秒前
15秒前
科研通AI6.3的应助被积极北上采纳,获得10
15秒前
时老完成签到 ,获得积分10
16秒前
16秒前
Parker发布了新的文献求助10
18秒前
18秒前
hmv发布了新的文献求助10
19秒前
Arvin发布了新的文献求助10
19秒前
ar发布了新的文献求助10
20秒前
魏魏完成签到,获得积分10
20秒前
20秒前
zhzhzh发布了新的文献求助10
21秒前
Owen的应助被杨家南采纳,获得10
22秒前
22秒前
不吃鸭梨完成签到,获得积分10
24秒前
砍柴少年发布了新的文献求助10
24秒前
无限的含羞草完成签到,获得积分10
25秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643